Akeso (SZSC:9926) - Stock Price, News & Analysis

9926 Stock Overview

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.

9926 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	4/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 45.5% below our estimate of its fair value

Earnings are forecast to grow 10.79% per year

Became profitable this year

Analysts in good agreement that stock price will rise by 22.8%

Risk Analysis

Shareholders have been diluted in the past year

Akeso, Inc. Competitors

Shanghai Henlius Biotech

SEHK:2696

HK$8.9b

Shanghai Haohai Biological Technology

SEHK:6826

HK$15.5b

3SBio

SEHK:1530

HK$15.0b

HBM Holdings

SEHK:2142

HK$864.6m

Price History & Performance

Summary of all time highs, changes and price drops for Akeso
Historical stock prices
Current Share Price	HK$48.15
52 Week High	HK$55.00
52 Week Low	HK$30.30
Beta	0.48
1 Month Change	3.44%
3 Month Change	20.68%
1 Year Change	10.06%
3 Year Change	-6.41%
5 Year Change	n/a
Change since IPO	27.55%

Recent updates

Shareholder Returns

	9926	HK Biotechs	HK Market
7D	-0.6%	4.3%	2.6%
1Y	10.1%	-37.2%	-7.4%

Return vs Industry: 9926 exceeded the Hong Kong Biotechs industry which returned -37.2% over the past year.

Return vs Market: 9926 exceeded the Hong Kong Market which returned -7.4% over the past year.

Price Volatility

Is 9926's price volatile compared to industry and market?
9926 volatility
9926 Average Weekly Movement	6.6%
Biotechs Industry Average Movement	9.4%
Market Average Movement	7.4%
10% most volatile stocks in HK Market	15.0%
10% least volatile stocks in HK Market	3.6%

Stable Share Price: 9926 has not had significant price volatility in the past 3 months.

Volatility Over Time: 9926's weekly volatility (7%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2012	2,778	Michelle Xia	www.akesobio.com

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors. It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.

Akeso, Inc. Fundamentals Summary

How do Akeso's earnings and revenue compare to its market cap?
9926 fundamental statistics
Market cap	HK$41.69b
Earnings (TTM)	HK$2.19b
Revenue (TTM)	HK$4.89b

19.3x

P/E Ratio

8.6x

P/S Ratio

Is 9926 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
9926 income statement (TTM)
Revenue	CN¥4.53b
Cost of Revenue	CN¥137.51m
Gross Profit	CN¥4.39b
Other Expenses	CN¥2.36b
Earnings	CN¥2.03b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	2.34
Gross Margin	96.96%
Net Profit Margin	44.81%
Debt/Equity Ratio	65.7%

How did 9926 perform over the long term?

See historical performance and comparison

9926 Stock Overview

Rewards

Risk Analysis

Akeso, Inc. Competitors

SEHK:2696

HK$8.9b

SEHK:6826

HK$15.5b

SEHK:1530

HK$15.0b

SEHK:2142

HK$864.6m

Price History & Performance

Recent News & Updates

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Recent updates

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

National Medical Products Administration Accepted the Supplemental New Drug Application by Akeso, Inc. for (Cadonilimab, Pd-1/Ctla-4) as First-Line Treatment for Cervical Cancer

New minor risk - Shareholder dilution

Akeso, Inc. has completed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Akeso, Inc. has filed a Follow-on Equity Offering in the amount of HKD 1.18172 billion.

Full year 2023 earnings released: EPS: CN¥2.42 (vs CN¥1.42 loss in FY 2022)

Investor sentiment improves as stock rises 15%

Akeso, Inc. to Report Fiscal Year 2023 Results on Mar 18, 2024

Akeso Announces the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-Line Treatment of PD-L1 negative NSCLC

Akeso Presents Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI

Akeso, Inc. Announces Innovative Clinical Development Roadmap

Akeso, Inc. Announces National Medical Products Administration Accepts the Supplemental New Drug Application for Kai Tan Ni (Cadonilimab, PD-1/CTLA-4) in Combination with Chemotherapy as First-Line Treatment for Gastric Cancer

Akeso, Inc. Publishes Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-nave Acute Myeloid Leukemia at ASH 2023

Akeso Publishes Results from Three Investigator-Initiated Trials

Founder recently sold HK$96m worth of stock

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso (9926. Hk) Announces AK104-303 Phase III Trial Meets One of its Primary Endpoints of Progression-Free Survival (PFS) for First-Line Treatment of Recurrent/Metastatic Cervical Cancer

Akeso, Inc. Announces AK104-303, A Phase III Trial of Cadonilimab Reached Progression-Free-Survival Primary Endpoint At Interim Analysis for First Line Treatment of Cervical Cancer

Akeso's Cadonilimab (PD-1/CTLA-4) Phase III Trial Meets Primary Endpoint at Interim Analysis Demonstrating Strong Overall Survival Benefit as First-line Treatment in All-comer Patients with Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Co-Founder recently sold HK$4.4m worth of stock

Investor sentiment improves as stock rises 17%

Akeso Announces Results of Phase Ib Clinical Trial for PD-1/VEGF Bispecific Antibody

Akeso Announces the Publication of the Phase 1a/1b First-In-Human Study

Akeso, Inc. Announces Clinical Results from Cadonilimab in Patients with Advanced Solid Tumours (COMPASSION-03/AK104-201)

Akeso, Inc. Announces FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes

First half 2023 earnings released: EPS: CN¥3.02 (vs CN¥0.77 loss in 1H 2022)

New major risk - Revenue and earnings growth

Akeso Inc. Announces Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab (PD-1/VEGF) versus Pembrolizumab in First-Line PD-L1 Positive Advanced NSCLC

Akeso, Inc. Announces the National Medical Products Administration Accepts the New Drug Application for the Ebdarokimab Injection (IL-12/IL-23 Monoclonal Antibody, AK101)

Akeso Inc. Announces First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-Line Treatment of Squamous NSCLC

Akeso, Inc. to Report First Half, 2023 Results on Aug 29, 2023

New minor risk - Share price stability

Akeso, Inc., Annual General Meeting, Jun 28, 2023

NMPA Accepts Akeso's Ebronucimab (PCSK9 ) Marketing Application in Two Cardiovascular Indications

No longer forecast to breakeven

Full year 2022 earnings released: CN¥1.42 loss per share (vs CN¥1.32 loss in FY 2021)

Forecast to breakeven in 2023

Akeso, Inc. Announces China NMPA Approved Anniko (Penpulimab) for First-Line Treatment of Locally Advanced or Metastatic Squamous NSCLC

Akeso Inc. Announces JITC publication of Akeso's Ligufalimab(CD47 monoclonal antibody) Mechanism Shows Promising Antitumor Efficacy and Favorable Safety Profile

Forecast to breakeven in 2023

No longer forecast to breakeven

Less than half of directors are independent

Akeso, Inc. Announces Ivonescimab Granted Breakthrough Therapy Designation for I-O Resistance NSCLC Patients in China

Akeso Completes Enrollment in Phase III Trial of PD-1/VEGF Bispecific Antibody (AK112) Combined with Chemotherapy in EGFR-TKI-resistant nsq-NSCLC

Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific) in First-line Treatment of ES-SCLC on ACLC 2022

No longer forecast to breakeven

Akeso's Ivonescimab (PD-1/VEGF BsAbs) Granted Breakthrough Therapy Designation by China NMPA for the Treatment of Advanced NSCLC

Akeso, Inc. Develops Combination Therapies Based on Its PD-1 BsAbs, Ivonescimab (PD-1/VEGF) in Combination with Drebuxelimab (CD73) Approved for a Clinical Trial on Treating Advanced Solid Tumors

Akeso, Inc. Announces Commencement of Phase Ib/II clinical trial

Forecast to breakeven in 2024

Akeso, Inc. Publishes First Approval of Cadonilimab in Drugs, A Peer-Reviewed Medical Journal

Akeso, Inc. to Report First Half, 2022 Results on Aug 23, 2022

Akeso's Cadonilimab (Pd-1/Ctla-4), the First Dual Immune Checkpoint Inhibitor to Treat Cancer, Approved for Marketing in China

Akeso, Inc. Reports Results of Phase IB/II Clinical Trial of Ivonescimab Monotherapy for Advanced Non-Small Cell Lung Cancer Published At the 2022 ASCO Annual Meeting

Akeso, Inc. Announces Oral Presentation Featuring Promising Clinical Data of Cadonilimab (PD-1 CTLA-4 BsABs, AK104) for the First-Line Treatment of R/M Cervical Cancer at ASCO 2022

Akeso, Inc., Annual General Meeting, Jun 28, 2022

Less than half of directors are independent

Akeso, Inc. Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody(AK131)at the American Association for Cancer Research (AACR) 2022 Annual Meeting